dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
|---|---|---|---|---|
0.395289 | de7562e2ee234e749371883524de10b8 | Preliminary Screening produced a total of 54 articles and one publication identified by manual screening. | PMC9916383 | ijerph-20-02401-g001.jpg |
0.499287 | 942aa767050444e38e6fc2742d2035f8 | After jaw rehabilitation. | PMC9916383 | ijerph-20-02401-g002.jpg |
0.449358 | 64cd19e9dc3243599fd155e1f37dbbc1 | Postoperative orthopantomography in the upper arch. | PMC9916383 | ijerph-20-02401-g003.jpg |
0.436626 | 13ed330de0424fc6b02cf5f629b2fb62 | Surgical site after excision of compromised elements. | PMC9916383 | ijerph-20-02401-g004.jpg |
0.454369 | 5c1aacbe7677466d8165056bbc1e453f | Surgical site after excision of compromised elements. | PMC9916383 | ijerph-20-02401-g005.jpg |
0.420946 | ae5d668dfab148158e4db5d13148d679 | Occlusal view of the prosthetic rehabilitation. | PMC9916383 | ijerph-20-02401-g006.jpg |
0.496147 | d40af082de2041119688fc807cc3e47d | Frontal view of the prosthetic rehabilitation. | PMC9916383 | ijerph-20-02401-g007.jpg |
0.463781 | 87b0f5faab4746158d2d411a474e85e6 | CBCT Panorex projection of the clinical case at the follow up. | PMC9916383 | ijerph-20-02401-g008.jpg |
0.411422 | e0b5c92014b54fc6b0c754e439b94564 | CBCT Cross section projection of the clinical case at the follow up. | PMC9916383 | ijerph-20-02401-g009.jpg |
0.407081 | eec4d60e1bf7411b970aecc287c503ac | Score plots (PCA) showing separation indicating differences in the metabolomic patterns of the samples based on the time interval at which they were collected. (A) positive ionization mode, (B) negative ionization mode. | PMC9916698 | ijms-24-02127-g001.jpg |
0.470145 | f157b7ad04ac468bb384c0883f810dac | Heatmap showing the overall levels of the metabolites differentiating the samples collected at each time interval (Ward’s clustering algorithms, Euclidean distances). (A) Positive ionization mode, (B) negative ionization mode. The dark red squares on the heat map indicate a high abundance of that feature in a specific group of samples, whereas dark blue indicates a low abundance. | PMC9916698 | ijms-24-02127-g002.jpg |
0.460441 | 84eb68b45e8c4be2897ab43eb1219d9e | Selected metabolites differentiating the HBD and 30′DCD groups. The boxplots display the normalized peak areas, while the height of the rectangle represents the peak areas in the interquartile range (Q1 and Q3). The upper whisker denotes the largest data point excluding any outliers, and the lower whisker indicates the lowest data point excluding any outliers. The median normalized peak area of each group is indicated with a yellow square. *—p < 0.05; **—p < 0.01; blue = baseline; green = reperfusion. | PMC9916698 | ijms-24-02127-g003.jpg |
0.412929 | ff63b84fce184708abacaeeb16dc14e3 | Score plots (PCA) showing the separation between groups with different ischemic times prior to organ harvest. (A) Positive ionization mode, (B) negative ionization mode. | PMC9916698 | ijms-24-02127-g004.jpg |
0.442092 | 317c77ac2eae4dc287fc71303d2aeb27 | Selected compounds with levels linearly correlated with ischemia time prior to organ harvest. The boxplots show the normalized peak areas, and the height of the rectangles represent the peak areas in the interquartile range (Q1 and Q3). The upper whiskers indicate the largest data point, excluding any outliers, while the lower whiskers indicate the lowest data point, excluding any outliers. The median normalized peak area of each group is indicated with a yellow square. | PMC9916698 | ijms-24-02127-g005.jpg |
0.51969 | bbb5f3617efc4013aee011b3d472a34f | Changes in the levels of selected metabolites in the peri-transplant period. The plots display the medians of the normalized peak areas. The upper whisker denotes the largest data point, excluding any outliers, while the lower whisker indicates the lowest data point, excluding any outliers. *—p < 0.05; **—p < 0.01. | PMC9916698 | ijms-24-02127-g006.jpg |
0.421038 | 0d32e2e584be4efda76d3cfc5392f528 | Experimental groups and design. Prior to procurement, animals were subjected to 0 min (HBD; heart beating donors), 30 min, 60 min and 90 min of warm ischemia to mimic donation-after cardiac death (DCD). Gray dots represent bile sampling time points. SHAM—prior to organ harvest; BL—baseline (start of reperfusion); WIT—warm ischemia time. | PMC9916698 | ijms-24-02127-g007.jpg |
0.486652 | bb873163e40e408eb81860ebda00a06f | The development of the CSC theory. The theory of SCs and CSCs was initially conceived one and a half centuries ago. Virchow and Cohnheim first proposed the embryonic origin of cancer in 1870s. It took more than half a century until Furth and Kahn successfully established a mouse leukemia model indicating the possibility of tumor initiation by a minority of cancer cells. Since then, the CSC theory has been under challenge until more knowledge was accumulated. Today, the theory of CSCs has been substantiated and is regarded as reliable. CSCs have been demonstrated to be closely associated with EMT and metastasis [4,5,6,8,9,10,13,16,17,18]. | PMC9917228 | ijms-24-02555-g001.jpg |
0.457393 | 2ba6c9a0467d4c72908c07fec081eb56 | CSCs play a crucial role in metastasis due to their unique characteristics. Undergoing conventional standard anti-cancer therapies and the multi-directional influences from TME are cellular stress factors that CSCs are supposed to survive by activating an EMT program and stay in a quiescent state to keep themselves alive during dissemination and adjustment to different conditions in a new TME, being stimulated to proliferate when successfully adjusted to distant organs/sites. TME, tumor microenvironment; CSC, cancer stem cell; EMT, epithelial mesenchymal transition; MET, mesenchymal epithelial transition. | PMC9917228 | ijms-24-02555-g002.jpg |
0.479475 | a91cbb06d2dd4ae99b4afb7076b43614 | Interactions of CSCs within the TME. A tumor tissue is a complex composition of tumor cells and tumor-associated host tissue cells, along with blood and lymphatic vessels, molecules such as cytokines (colored circles), and acellular structures such as ECM. There are multi-directional interactions within the TME. These interactions alter that TME into a CSC supportive niche, which is tightly linked with the presence of hypoxia, acidosis, ECM remodeling, nutrients alterations and necrotic processes. The niche supports both the survival and maintenance of the CSCs by facilitating the promotion of stemness and regulation of dormancy. | PMC9917228 | ijms-24-02555-g003.jpg |
0.405569 | 740f4665bed847d2884c37355bc5f689 | The EMT and its associated transcription factors. The EMT program requires the activation of a variety of TFs, including Snail and Slug, Zeb1 and Zeb2, Twist1 and Twist2, FOXC2 and GSC. It leads to the decreased expression of epithelial markers such as E-cadherin and increase the expression of mesenchymal markers such as N-cadherin. Accordingly, the morphologic and functional changes occur correspondently during the EMT process. The EMT regulation mediated by TFs has been proposed as a central key factor in the acquisition of stemness and promotion of metastasis. E, epithelial; M, mesenchymal; TFs, transcription factors; αSMA, alpha smooth muscle actin; MMPs, matrix metallopeptidases. | PMC9917228 | ijms-24-02555-g004.jpg |
0.443992 | 7675160bb5eb4b71a3a2fcfd4513c155 | The invasion–metastasis cascade during cancer dissemination. Cancer cells acquire the necessary capabilities to complete the invasion–metastasis cascade. Firstly, the cancer cells at the primary tumor site spread into the surrounding tissue and pass through the epithelial basement membrane. Next, those cells successfully get access and invade into lymphatic and/or blood vessels (intravasation). These cells have to maintain cell viability during traveling in the circulation. When arriving at distant site(s), those disseminated cancer cells migrate out from the vessels (extravasation) to colonize in the target organ. Upon the process, small cell clones or disseminated cancer cells (micro-metastasis) must survive and finally, adjust to the new microenvironment, proliferate and form macroscopic metastasis (macro-metastasis). E, epithelial; M, mesenchymal; EMT, epithelial–mesenchymal transition; MET, mesenchymal–epithelial transition. | PMC9917228 | ijms-24-02555-g005.jpg |
0.495863 | ff9b2113d9554c078f968ebbac965de8 | The Rho GTPase signaling cycle. Rho GTPases typically cycle between the active GTP-bound active form and the GDP-bound inactive form. This GTP-binding/GTP-hydrolysis cycle is primarily regulated by three classes of proteins: GEFs, GAPs, and GDIs. GEFs catalyze the exchange of GDP to GTP, activating the Rho GTPase, while the GAPs inactivate the RhoGTPase by hydrolyzing the GTP. The GDIs sequester and extract the Rho GTPases from the membrane to prevent the interactions between Rho and GEFs, GAPs, and downstream effectors. The activated Rho GTPase turns on effectors to transduce signals leading to platelet cell functional changes. | PMC9917354 | ijms-24-02519-g001.jpg |
0.467 | 4e4ee1cffe9041ebbefd412475171871 | Role of RhoA in platelet activation and aggregation. RhoA works downstream of multiple G-protein coupled receptors and integrins to mediate platelet shape change, spreading, secretion, and clot retraction. Gα13 activates RhoGEF promoting RhoA-GTP formation, which eventually phosphorylates its downstream effector Myosin light chain (MLC), resulting in shape change and secretion. Gα13 also interacts with integrin αIIbβ3 to activate Src family kinases, which activate RhoGAP, which leads to RhoA inhibition, allowing platelets to spread. Calcium released during the initial stages of platelet activation causes calpain to cleave integrin β3 inhibiting c-Src activation to promote contractility and clot retraction. In addition to Gα13, Gq/11 also contributes to platelet activation via calcium/calmodulin-mediated MLC kinase activation. | PMC9917354 | ijms-24-02519-g002.jpg |
0.472808 | ca3fcef0574f4833a00e86f2ecb984e6 | Pharmaceutical targeting of Rho GTPases as an antiplatelet approach. Various pharmacological inhibitors have been developed to selectively target critical components of the Rho GTPase signaling pathways and inhibit platelet activation. RhoA inhibitors such as Rhosin, Y16, and ROCK inhibitors such as Y27632 and Fasudil have been used to study the role of RhoA in platelet function. NSC23766, EHop-016, and EHT-1864 inhibit the activation of Rac1, while CASIN, Secramine, and ML141 inhibit the activation of Cdc42 to study their roles in platelet activation. IPA 3, an inhibitor of PAK, is used to elucidate the role of PAK in platelet function. | PMC9917354 | ijms-24-02519-g003.jpg |
0.417877 | 69ea0798784548959f8c2aabf7f1a8ea | The main processes within neuro-muscular junction known to be affected by snake venom sPLA2 crotoxin: 1—binding to a specific site at presynaptic membrane (presumably to N-type sPLA2 receptor); 2—a general membrane-destabilizing effect and phospholipolysis; 3—translocation across the membrane using the synaptic vesicle recycling machinery; 4—binding to proteins 14-3-3 for localization inside the nerve ending; 5—stabilization by calmodulin with increasing the enzymatic activity; 6—enhancement of exocytosis of acetylcholine (Ach) by products of phospholipolysis; 7—retrograde trafficking provided by protein disulfide isomerase (PDI); 8—putative crossing the outer mitochondrial membrane; 9—binding to subunit II of mitochondrial cytochrome c oxidase (CcO); 10—binding to and block of a nicotinic acetylcholine receptor (nAChR) at postsynaptic membrane. Crotoxin structure is from PDB bank (ID 3R0L). | PMC9917609 | ijms-24-02919-g001.jpg |
0.450524 | a4cc22ec03924afe979aaeea9baf32c3 | (a) Amino-acid sequences of azemiopsin and waglerins. Homologous fragments are underlined. AZE—azemiopsin (UniProt KB-B3EWH2) from A. feae; WAG-1 (UniProt KB-P24335), WAG-2 (UniProt KB-P58930), WAG-3 (UniProt KB-P24335) and WAG-4 (UniProt KB-P58930) are waglerin-1, 2, 3 and 3, respectively, from T. wagleri. (b) Amino acid sequences of baptides from B. arietans. | PMC9917609 | ijms-24-02919-g002.jpg |
0.399132 | c725eaeaf8ac4672bd38e66b8668cc75 | Amino acid sequences of sarafotoxins. Disulfide bonds are shown as lines connecting cysteine residues. Identical amino acid residues are underlined. SRTX-A (UniProtKB-P13208), SRTX-B (P13208), SRTX-C (P13208), SRTX-E (P13208), and SRTX-D (P13211) are sarafotoxins a, b, c, e, and d from A. engaddensis venom, respectively. SRTX-i1 (P0DJK0) is sarafotoxin i1 from A. irregularis venom; SRTX-m (Q6RY98) is sarafotoxin m from the venom of A. microlepidota microlepidota. | PMC9917609 | ijms-24-02919-g003.jpg |
0.459526 | 1f53b3845220493c990484fb208d4a4b | Clinical presentation of unilateral condylar hyperplasia and facial asymmetry. (A) chin deviation with a class III trend; (B) lack in dental midline and unilateral crossbite dental occlusion. | PMC9917662 | jcm-12-01017-g001.jpg |
0.468185 | 65defbe8f4564eaead0e295158e42140 | Classification of the facial asymmetry related to unilateral condylar hyperplasia. (A) type 1, with a horizontal component with UCH on the right side; (B) type 2, with a vertical component with UCH on the left side; (C) type 3, with a horizontal and vertical component and UCH on the left side. | PMC9917662 | jcm-12-01017-g002.jpg |
0.419128 | b8273114d3124830a2396ada00d282ff | Hyperplastic growth of the condyle on the left side in different subjects showing progressive facial asymmetry. (A) Young subject with an augmented condyle on the left side (note the augmented articular space in the right TMJ with a normal size of the condyle). (B) Augmented condyle on the left side with more differences in height and width compared to the right condyle in an older subject. | PMC9917662 | jcm-12-01017-g003.jpg |
0.412978 | b5c426df931c49458d50e715739298c2 | CBCT of the same subject in sagittal view. (A) left condyle in normal growth and (B) right condyle with hyperplastic growth involving neck and ramus of the same side of the mandible. The progressive asymmetry will move all the sides involved in the abnormal growth of the condyle. | PMC9917662 | jcm-12-01017-g004.jpg |
0.481368 | ebfbebb4edea4931989a460b2d07df29 | Surgeons’ responses to the questionnaire regarding low and high anal fistulas (chi-squared test). QoL = quality of life; Even if = considerable. | PMC9918049 | jcm-12-00825-g001.jpg |
0.399824 | dece81704c6d458999ad0c2ef86ed1dc | Comparison of respondents’ opinions between who would and would not agree to be submitted to fistulotomy in low and high anal fistula, separately (chi-squared test). QoL = quality of life; Even if = considerable. | PMC9918049 | jcm-12-00825-g002.jpg |
0.377801 | 9e29aa379c704530b0b22dc0298d6466 | Comparison of respondents’ opinions between who would and would not agree to be submitted to fistulotomy in both low and high anal fistula (chi-squared test). QoL = quality of life; Even if = considerable. | PMC9918049 | jcm-12-00825-g003.jpg |
0.473489 | 3c0fe37835bb4a3ea6ff5182de3a89e4 | The overall study process flow. | PMC9918153 | materials-16-00935-g001.jpg |
0.470117 | 5c7b9ed40b24457a8fecd0f0f155d9cf | The sketch and setup of a geometrical panel (a) with its dimensions and (b) in the four-point bending simulation. | PMC9918153 | materials-16-00935-g002.jpg |
0.457478 | aed8b0e0f753410a88856b748a6e1c19 | Example of stress distribution under the four-point bending simulation. | PMC9918153 | materials-16-00935-g003.jpg |
0.434523 | ad95241c73f447799942262c27c7db5f | Example of total deformation distribution under the four-point bending simulation. | PMC9918153 | materials-16-00935-g004.jpg |
0.50792 | 1589a09284a54a96831dc6f884ced79f | The mesh sensitivity analysis for meshing sizes between 0.8 to 1.2 mm, with different core designs shown for comparison. | PMC9918153 | materials-16-00935-g005.jpg |
0.45716 | 53b5fb2768604f338d8498aa81c1eaaf | The developed hierarchical tree determined from finite element analysis (FEA). | PMC9918153 | materials-16-00935-g006.jpg |
0.465001 | ecfddf9e7d4a4db286a76ddcedf5fa76 | The main steps to determine the fuzzified weights for each criterion using the F-AHP method. | PMC9918153 | materials-16-00935-g007.jpg |
0.456994 | ce4a24454f334433b95106ecc04dbc8f | The steps to determine the best core design selection using the F-TOPSIS method. | PMC9918153 | materials-16-00935-g008.jpg |
0.436209 | 8e1e89342e154a71bdb5a5b9e594cfc6 | The stress distribution on a simulated panel under cyclic loading conditions (units in MPa): (a) 70%, (b) 50%. | PMC9918153 | materials-16-00935-g009.jpg |
0.440621 | ab19dcc777fc4d33ad6c7cbef0bf147c | The stress distribution on the bonding area of a simulated panel under cyclic loading conditions (units in MPa): (a) 70%, (b) 50%. | PMC9918153 | materials-16-00935-g010a.jpg |
0.454867 | a1e7783da8c14fb28d45e92576dc3563 | The permanent deformation experienced by a simulated panel under cyclic loading conditions (units in mm): (a) 70%, (b) 50%. | PMC9918153 | materials-16-00935-g011.jpg |
0.475681 | 352ac06729d540108797bdcbfdb653f0 | The life cycle (denoted as Nf), at the core panel of a simulated panel under cyclic loading conditions (units in cycle): (a) 70%, (b) 50%. | PMC9918153 | materials-16-00935-g012a.jpg |
0.482217 | dd8a08d8809146b499856e0368eecbec | The maximum damage points region (indicated with red circles—see the zoom-in) on the core panel under cyclic loading conditions of: (a) 70%, (b) 50% (no unit for the damage value as the maximum damage value is equal to 1). | PMC9918153 | materials-16-00935-g013.jpg |
0.510157 | c5190cac12fa4b2fbcec9ffe898296e4 | The ranking (read from highest to lowest value) between the dimple core design alternatives under cyclic loading conditions of 50% and 70%. | PMC9918153 | materials-16-00935-g014.jpg |
0.434807 | e4793a121eb249c088389ca0ce83373e | The model of damage in a logarithmic scale showing the maximum damage to the hotspot dimple region against the number of stress life cycles for various dimple core configurations under constant cyclic loading conditions. | PMC9918153 | materials-16-00935-g015.jpg |
0.37861 | b70944c4f6664aa1a0fb810905117e06 | Simulation result at t = 3 in a homogeneous medium of τ = 4. | PMC9918304 | nihms-1868959-f0001.jpg |
0.396726 | cb471cfb60824c5eb45ef4f283ceec8b | Realizations of Cauchy random fields with columns (from left to right) at α = 0.2, 1.0, 1.8 and horizontal rows (from top to bottom) β = 1.0, 1.4, 1.8. | PMC9918304 | nihms-1868959-f0002.jpg |
0.497536 | 94efcb00741e4e5cac7a9e6bb2ef791e | Realizations of Dagum random fields with columns (from left to right) at α = 0.4, 0.6, 0.8 and horizontal rows (from top to bottom) β = 0.2, 0.4, 0.6, 0.8. | PMC9918304 | nihms-1868959-f0004.jpg |
0.464108 | 4af4a2c8421e4915999415ce76c04cf6 | Simulation result at t = 3 in Cauchy random fields with columns (from left to right) at α = 0.2, 1.0, 1.8 and horizontal rows (from top to bottom) β = 1.0, 1.4, 1.8. | PMC9918304 | nihms-1868959-f0006.jpg |
0.47305 | 37a022a8f20641869358601e3d3365df | Simulation result at t = 3 in Dagum random fields with columns (from left to right) at α = 0.4, 0.6, 0.8 and horizontal rows (from top to bottom) β = 0.2, 0.4, 0.6, 0.8. | PMC9918304 | nihms-1868959-f0008.jpg |
0.421871 | cc84d4b9baec4386a019bd1e9b3b2720 | Schematic diagram of the one-dimensional three-segment composite granular chain. | PMC9919325 | materials-16-01282-g001.jpg |
0.406442 | 0bf3db714cf2492f82d434f5a21d5164 | Finite element mesh of the granules: (a) meshes of two adjacent granules; (b) locally refined meshes in the contact areas. | PMC9919325 | materials-16-01282-g002.jpg |
0.456449 | 7328ea8dda9e49b6bd0ec7dd9475dd20 | Comparison of impact wave propagation in elastic granular chains and elastic–plastic granular chains: (a) Homogeneous elastic granular chain (V0 = 0.45 m/s, E = 200 GPa, ν = 0.3, ρ = 7800 kg/m3); (b) Homogeneous elastic–plastic granular chain (λ = 1); (c) Heterogeneous elastic–plastic granular chain (λ = 0.23). | PMC9919325 | materials-16-01282-g003.jpg |
0.437806 | 507fb2187071436aa29b8d72196c83ad | Velocity-time curves of the first three granules: (a) Homogeneous elastic granular chain; (b) Homogeneous elastic–plastic granular chain (λ = 1). | PMC9919325 | materials-16-01282-g004.jpg |
0.429992 | c8a86e02b1e44a5d84a78748e6de69e6 | Contact force-time curves at different granule positions of Case 3 (λ = 1): (a) Granules 9 and 10 in homogeneous elastic–plastic granular chain; (b) Granules 7 and 8 in an inhomogeneous elastic–plastic granular chain. | PMC9919325 | materials-16-01282-g005.jpg |
0.445681 | 3bcf1b724d4b44fba5bda5117ed42780 | Contact force-deformation curves at different granule positions in six cases: (a) Contact force versus deformation of granule 5; (b) Contact force versus deformation of granule 6; (c) Contact force versus deformation of granule 10; (d) Contact force versus deformation of granule 11. | PMC9919325 | materials-16-01282-g006.jpg |
0.446323 | 2c13853e08ec4a10bb7c4d4871f89650 | Multiple loading and unloading behaviors in Case 3 (λ = 1): (a) Contact force-deformation curve of the contact pair between granule 10 and granule 11; (b) Contact force-time curve of the contact pair between granule 10 and granule 11. | PMC9919325 | materials-16-01282-g007.jpg |
0.491637 | c3523f36f93041618ce5b2e9e9ef4bc3 | Contact force-time curves of Part II input interface and output interface under six cases. | PMC9919325 | materials-16-01282-g008.jpg |
0.41976 | 86d25a6a1d11453c85a3e71ca5c34758 | The impact buffering performance in Part II: (a) maximum contact force; (b) amplitude ratio and the time delay. | PMC9919325 | materials-16-01282-g009.jpg |
0.472309 | d64299e2851f40bbb70d2b4f561b4533 | The impact buffering performance in the granular chain: (a) force-time history; (b) the energy dissipation and time delays. | PMC9919325 | materials-16-01282-g010.jpg |
0.42266 | a41daaaecbc345819351a707d9c400af | Wave velocity in the whole granular chain. | PMC9919325 | materials-16-01282-g011.jpg |
0.393732 | 0f95554ac896409a97c01921126098e6 | (A) Plant area, (B) leaf number, (C) shoot dry weight, (D) root dry weight, (E) root surface area, and (F) total root length of watermelon transplants irrigated with nutrient solution of different NaCl concentration and sprayed with two biostimulants. Within a bar, average values (n = 5) followed by different letters are significantly different (a < 0.05). | PMC9920198 | plants-12-00433-g001a.jpg |
0.402792 | 4de4324a7b8e401fa9c89e647f93de23 | (A) PIabs, (B) φP0, (C) ψE0, (D) RC/ABS, (E) VJ, and (F) ΔVIP of watermelon transplants irrigated with nutrient solution of different NaCl concentration and sprayed with two biostimulants. Within a bar, average values (n = 5) followed by different letters are significantly different (a < 0.05). | PMC9920198 | plants-12-00433-g002a.jpg |
0.481361 | c1417c01c0dd45c1843203ecfc02efa6 | OJIP parameters normalized to the values of the non-biostimulant treatments. (A) 0 mM NaCl, (B) 50 mM NaCl, and (C) 100 mM NaCl. Post hoc statistical analysis is displayed in Table 2. | PMC9920198 | plants-12-00433-g003.jpg |
0.432558 | 263c3554678843d787d704f67ca488a6 | Watermelon seedlings transplanted in pots, irrigated with nutrient solution of different NaCl concentration, and sprayed with two biostimulants. | PMC9920198 | plants-12-00433-g004.jpg |
0.468555 | aabe4b068fe34a86a51e84e5601ae864 | Flow diagram of this randomized, controlled, open-label trial. CRD, calorie-restricted diet. RCT, randomized controlled trial. | PMC9920202 | nutrients-15-00556-g001.jpg |
0.504797 | 78a643c924174ad3bc0fec6919511e6a | Time-to-event analysis of achieving 7% weight loss of initial body weight in the two groups. CRD, calorie-restricted diet; HR, hazard ratio. | PMC9920202 | nutrients-15-00556-g002.jpg |
0.423636 | 269e4b02ee854065857d78ae2cb4dd7c | The change in VAT area from baseline to reach 7% weight loss of initial body weight in the intention-to-treat population. CRD, calorie-restricted diet; LS, least-squares; VAT, visceral adipose tissue. | PMC9920202 | nutrients-15-00556-g003.jpg |
0.434784 | dcf67e54ca0f4288a5cef9ccd6b65a64 | rac-Et(2-MeInd)2ZrMe2 and isobuthylaluminum aryloxides used in the study. | PMC9921281 | polymers-15-00487-g001.jpg |
0.481101 | e0521c9c62d64253ad2d11f753fe2530 | DFT optimized structure of catalytically active center rac-Et(2-MeInd)2Zr+Pr…(2,6-tBu2-4-R-PhO-)Al–MeiBu, where R is para-substituent in the aryloxy fragment. | PMC9921281 | polymers-15-00487-g002.jpg |
0.501198 | 070be522e9f342ab9baa4f517366c24d | DSC thermograms for second cycle heating of pristine (a) and fractionated (b,c) E/P and E/P/ENB copolymers obtained on the rac-Et(2-MeInd)2ZrMe2/isobuthylaluminum aryloxide catalyst systems. | PMC9921281 | polymers-15-00487-g003.jpg |
0.392961 | 3daea37904df4624a251132d469924dc | Temperature dependencies (at 1 Hz) of E′ (a) and E″ (b) for E/P copolymers obtained on catalytic systems with mono- and dimeric aryl oxides (1) 1-DTBP, (6) 1-MTBP, (4) 2-DTBP, and E/P/ENB terpolymers obtained on catalytic systems with (8) 1-DTBP and (11) 2-DTBP. Numbers on the curves match the entries in Table 1 and Table 3. | PMC9921281 | polymers-15-00487-g004.jpg |
0.462662 | 59d19a04e2574b2e99c90ae1ba731930 | Stress–strain diagrams for E/P samples 1–5, 7 and E/P/ENB samples 8–12, 14, produced by rac-Et(2-MeInd)2ZrMe2/isobutylaluminum aryloxide catalytic systems. Aryloxides are 1, 8—1-DTBP; 2, 9—1-BHT, 3, 10—1-TTBP; 7, 14—1-DPP; 4, 11—2-DTBP, 9, 12—2-BHT. | PMC9921281 | polymers-15-00487-g005.jpg |
0.461606 | 6b2600f34b104a2e976b7cb3b5026249 | The effect of phenol antioxidant on thermooxidative destruction of E/P copolymers. TGA of polymers produced by rac-Et(2-MeInd)2ZrMe2/activator catalytic system, activator = IBAO (isobutylalumoxane), 1-DTBP, 1-BHT, 1-TTBP, 1-MTBP, 1-DPP. | PMC9921281 | polymers-15-00487-g006.jpg |
0.406907 | b32694cbd6dc4961bdcca011773df8c3 | Different applications for gallic acid. | PMC9921589 | molecules-28-01166-g001.jpg |
0.562617 | 7085f75f54344848b0df0cd8a53d5729 | Reduction of Fe3+ ions by gallic acid and its oxidized intermediates. The regenerated Fe2+ ions can react with H2O2 to generate more HO● radicals via Fenton reaction. This illustration was adapted from Christoforidis et al. [18], with permission from John Wiley and Sons (ON 5460750316371). | PMC9921589 | molecules-28-01166-g002.jpg |
0.50817 | e0dfd158cd184abc8b433d5c453c8baa | The structure of the Zn-MOF: (a) the coordination environment of Zn ion, (b) the three-dimensional framework, (c) left- and right-handed helix chains of Zn1-BMP, and (d) left- and right-handed helix chains of Zn1-BMP-Zn1-L. | PMC9921817 | molecules-28-00999-g001.jpg |
0.506762 | 1f99687eba704ce490fe043671ba6458 | The solid-state emission spectra of the H3L/BMP ligands and the Zn-MOF. | PMC9921817 | molecules-28-00999-g002.jpg |
0.46255 | 3b39c8fc692b4c7caca078ea15442cac | (a) The PXRD patterns of the Zn-MOF, and (b) the luminescence intensity of the Zn-MOF in different pH aqueous solutions. | PMC9921817 | molecules-28-00999-g003.jpg |
0.503945 | 353c10c59b614687a00f643d66ad2f77 | Luminescence emission spectra of the Zn-MOF in different solvents. | PMC9921817 | molecules-28-00999-g004.jpg |
0.440186 | 8b09a66773e242fab40846fed3916791 | (a) Emission spectra of the Zn-MOF with the addition of acetone and (b) the SV plot for the quenching effect of acetone on the luminescence of the Zn-MOF under 305 nm. | PMC9921817 | molecules-28-00999-g005.jpg |
0.412915 | d4d6058c210f4c9594124b012f1d3c09 | (a) Emission spectra of the Zn-MOF in the presence of different antibiotics, (b) luminescence intensity of the Zn-MOF in the presence of other interfering antibiotics with TC and without TC, (c) emission spectra of the Zn-MOF with the addition of TC, and (d) the SV plot for the quenching effect of TC on the luminescence of the Zn-MOF (λex = 305 nm). | PMC9921817 | molecules-28-00999-g006.jpg |
0.49217 | 955cf1eebfac437a901f6dcda8267180 | (a) Emission spectra of the Zn-MOF with the addition of TC (pH = 4), (b) the SV plot for the quenching effect of TC on the luminescence of the Zn-MOF (pH = 4), (c) emission spectra of the Zn-MOF with the addition of TC (pH = 10), and (d) the SV plot for the quenching effect of TC on the luminescence of the Zn-MOF (pH =10). | PMC9921817 | molecules-28-00999-g007.jpg |
0.421958 | e57fe7c63f00464e89a36012833a47a0 | Luminescence intensity of the Zn-MOF in urine (a) and in the aquaculture wastewater system (b). | PMC9921817 | molecules-28-00999-g008.jpg |
0.366623 | dafda0c1c9b14a1dbfc53e7acb72768c | (a) PXRD pattern of the Zn-MOF after luminescence sensing of TC and acetone, and (b) excitation and emission spectra of the Zn-MOF and UV absorption spectra of TC and acetone. | PMC9921817 | molecules-28-00999-g009.jpg |
0.497268 | 4cbb62fcd5eb4813af6681749a66cefc | HOMO and LUMO of ligands BMP, H3L, acetone, and TC. | PMC9921817 | molecules-28-00999-g010.jpg |
0.433841 | 651c08724d054cadac39cddb8b985dd3 | The construction and luminescence sensing of the Zn-MOF. | PMC9921817 | molecules-28-00999-sch001.jpg |
0.462476 | 01c18aaec13048e482d05e4c3a08efa4 | Synthesis of the two worlds of genetics: from behavioral genetics to behavioral genomics. | PMC9922236 | 10519_2023_10132_Fig1_HTML.jpg |
0.519221 | 2af3f76e3fca4c11a69f2244a058c810 |
Prevalence of multimorbidity by age using four different definitions. Multimorbidity 2+ = ≥2 long-term conditions (LTCs). Multimorbidity 3+ = ≥3 LTCs. Multimorbidity 3+ from 3+ = ≥3 LTCs from ≥3 International Classification of Diseases, 10th revision chapters. Mental–physical multimorbidity = ≥2 LTCs where ≥1 mental health LTC and ≥1 physical health LTC are recorded.
| PMC9923763 | bjgpapr-2023-73-729-e249-1.jpg |
0.533603 | f63b51c229904f95a6e27dd7055d6f1d |
Prevalence of each definition of multimorbidity in the most and least deprived IMD decile, by age. Graphical representation of the estimated multimorbidity prevalence for each of the four definitions, comparing the most and least deprived IMD decile. 95% confidence intervals are represented by coloured vertical lines. Dashed vertical black lines represent the point at which the horizontal gap (difference in multimorbidity prevalence) between most and least deprived IMD deciles is largest (that is, where there is greatest inequality in the age at which people have multimorbidity). IMD = Index of Multiple Deprivation. Multimorbidity 2+ = ≥2 long-term conditions (LTCs). Multimorbidity 3+ = ≥3 LTCs. Multimorbidity 3+ from 3+ = ≥3 LTCs from ≥3 International Classification of Diseases, 10th revision chapters. Mental–physical multimorbidity = ≥2 LTCs where ≥1 mental health LTC and ≥1 physical health LTC are recorded.
| PMC9923763 | bjgpapr-2023-73-729-e249-2.jpg |
0.433362 | 22115d64084a4eddabe66684f56affc6 | Lateral knee X-Rays showed increased Insall-Salvati Index (Left: 2.0, Right: 2.1).[1]
Fig. 1c. Intra-op findings of a patellar tendon rupture occurring at the inferior pole, with damage to the retinaculum. Fig. 1d. Left and right patellar tendons were repaired surgically using non-absorbable suture Krakow stiches. Fig. 1e. The repair was re-enforced with non-absorbable mesh tape arranged in a figure-of-eight pattern around the circumference of the patella and through a horizontal drill-hole in the tibial tubercle. | PMC9924605 | 2078-516X-34-v34i1a11781-g001.jpg |
0.408498 | 0ed079731cfa484ebf6fab90fb5d12c4 | EU and participant inclusion by elimination group.Observations from the most recent surveys (denoted with a t) were the basis for the study populations, while observations from the prior surveys (denoted with a t-1) were used to calculate EU-level measures used for confounding adjustments. 69 EUs (n = 253,017 individuals) had a survey sequence of baseline-impact-surveillance and were therefore included in both the reaching elimination target EUs and in the adjustment EUs for the maintaining elimination target EUs. | PMC9925017 | pntd.0011103.g001.jpg |
0.472812 | b18ae8c9ac3c4ef5a385268002121976 | Prevalence difference and number and percentage of EUs modified after implementing hypothetical interventions on nearby face-washing water and latrine coverages among reaching elimination target EUs.These figures show the results presented in Table 2 graphically for (a) nearby face-washing water interventions, (b) latrine interventions, and (c) simultaneous interventions on both nearby face-washing water and latrines for the reaching elimination target EUs. When present, the vertical bar indicates the minimum coverage target at which the relative prevalence decrease was at least 25%. | PMC9925017 | pntd.0011103.g002.jpg |
0.458532 | 9eef9e56ed9842e49aaf84954d4e7856 | Prevalence difference and number and percentage of EUs modified after implementing hypothetical interventions on nearby face-washing water and latrine coverages among maintaining elimination target EUs.These figures show the results presented in Table 2 graphically for (a) nearby face-washing water interventions, (b) latrine interventions, and (c) simultaneous interventions on both nearby face-washing water and latrines for the maintaining elimination target EUs. When present, the vertical bar indicates the minimum coverage target at which the relative prevalence decrease was at least 25%. Shaded areas indicate values the prevalence difference cannot reach. | PMC9925017 | pntd.0011103.g003.jpg |
0.43164 | 91b4bb5a0ba44eeeb5cbe00454997710 | Patient flow chart. | PMC9925989 | ijmsv20p0219g001.jpg |
0.403532 | 9846c08b6a514464900f869d1a46b365 | Multivariate analysis for the risk of colorectal polyps. | PMC9925989 | ijmsv20p0219g002.jpg |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.